Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
Provided By GlobeNewswire
Last update: Sep 29, 2025
Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025
Read more at globenewswire.com
